Patricia Inácio, PhD,  science writer—

CSL Behring has won an award for its efforts to ensure patient access to therapies for hereditary angioedema (HAE). The company received the nod in the Biologics & Injectables category of the Patient Access Awards, launched this year by Managed Markets Insight & Technology (MMIT), a provider of…

More than one-third of people with hereditary angioedema (HAE) hesitate to have children of their own — often due to fears of passing on the chronic genetic disease — according to data from a small survey. “Our study showed that HAE has a clear impact on reproductive decision-making,” the…

Sebetralstat, KalVista Pharmaceuticals‘ investigational on-demand treatment for swelling attacks in people with hereditary angioedema (HAE), led to a rapid and sustained suppression of kallikrein in HAE patients, according to data from a Phase 2 trial. As previously reported, the use of sebetralstat also was associated with fast…

The first case of a patient developing angioedema accompanied by hives after treatment with solifenacin, a medication commonly used to treat urinary incontinence, was described in a recent case report. The report, “Solifenacin-induced acute urticaria and angioedema: a rare adverse effect,” was published in the Postgraduate Medical…

Lack of awareness about rare diseases, such as hereditary angioedema (HAE), contributes to their often long and delayed diagnosis, a study suggests. The study, “Why does it take so long for rare disease patients to get an accurate diagnosis?—A qualitative investigation of patient experiences of hereditary angioedema,” was…

Intellia Therapeutics has completed dosing the first group of patients enrolled in a Phase 1/2 clinical trial testing its gene-editing therapy, NTLA-2002, for the treatment of hereditary angioedema (HAE). In the Phase 1 part of the study (NCT05120830), patients will receive a single infusion of NTLA-2002, delivered into…

In rare cases, stroke-like symptoms, such as tingling in the face and the left arm, can occur during an acute attack of hereditary angioedema (HAE), a case study reports. The patient, a woman in her 30s, developed facial swelling and abdominal pain. All her symptoms resolved with treatment with…

Newbury Pharmaceuticals is launching its injectable therapy of icatibant, the active agent of Firazyr, in Sweden and Norway to treat acute attacks in people with hereditary angioedema (HAE). “Making Icatibant Newbury available in Sweden and Norway is an important milestone to Newbury as we see the fruits…

Orladeyo (berotralstat), an approved therapy for preventing swelling attacks in hereditary angiodema (HAE), was effective at controlling attacks in an HAE patient with normal C1 inhibitor activity, a case study reported. The clinician said this oral therapy may be particularly suitable for patients who have a needle phobia…

Short-term treatment with Berinert, a plasma-derived form of the C1 inhibitor protein, successfully prevented acute swelling attacks in a patient with hereditary angioedema (HAE) following oral surgery, a case report describes. The report, “Oral Surgery Procedures in a Patient Affected by Hereditary Angioedema Type I,” was published…